Medications That Can Affect Hair Loss

Hair loss can be stressful, confusing, and difficult to trace. Many people first look at diet, hormones, stress, or genetics. But one commonly overlooked contributor is medication.

Prescription and over-the-counter medications can sometimes trigger shedding, thinning, or changes in hair texture. This does not mean you should stop a medication on your own. In many cases, medication-related hair loss is temporary, manageable, or caused by a combination of factors.

This guide explains how medications may affect the hair cycle, which drug categories are commonly linked to shedding, and what to do if your hair loss started after a new prescription or dosage change.

Key Takeaways

• Medications can trigger hair shedding. This may happen through telogen effluvium, anagen effluvium, hormonal disruption, nutrient depletion, or inflammation.
• Timing matters. Some medication-related hair loss appears within days or weeks, while other forms appear 6 to 12 weeks after starting or changing a medication.
• Do not stop medication without medical advice. Speak with the prescribing doctor before changing dosage, stopping, or switching medication.
• Hair loss is often multifactorial. Medication may be one trigger alongside stress, low ferritin, thyroid imbalance, inflammation, or genetic pattern hair loss.
• A timeline is essential. Track medication start dates, dosage changes, shedding onset, illness, surgery, stress, and nutritional changes.

How Medications Can Cause Hair Loss

The scalp contains thousands of hair follicles, each moving through a cycle: anagen, catagen, and telogen. Anagen is the active growth phase. Catagen is the transition phase. Telogen is the resting and shedding phase.

Medications can affect this cycle in different ways. Some interrupt rapidly dividing cells. Others shift hairs into the resting phase, alter hormones, interfere with nutrient absorption, or increase inflammation.

Anagen Effluvium

Anagen effluvium happens when a medication disrupts hair follicles during the active growth phase. Because anagen hairs are rapidly dividing, they are especially vulnerable to drugs that interfere with DNA replication, mitosis, or cell division.

This type of hair loss can appear quickly, often within days to weeks. It is most commonly associated with chemotherapy and other cytotoxic drugs. Hair may become fragile and break close to the scalp, sometimes causing dramatic shedding.

Telogen Effluvium

Telogen effluvium is a delayed shedding pattern. A medication or physical stressor pushes more hairs than usual from the growth phase into the resting phase. The shedding usually becomes noticeable 6 to 12 weeks later.

This is one of the most common forms of medication-related hair loss. It often appears as diffuse shedding across the scalp rather than bald patches.

Hormonal Disruption

Some medications affect hormones such as testosterone, estrogen, progesterone, thyroid hormones, or cortisol. These shifts can trigger shedding or worsen existing androgenetic alopecia in people who are genetically sensitive.

Nutrient Depletion or Malabsorption

Some drugs can interfere with the absorption or metabolism of nutrients needed for hair growth. These may include iron, zinc, biotin, folate, vitamin D, and vitamin B12.

This matters because hair follicles depend on steady nutrient availability for keratin production, cell division, and normal cycling.

Inflammation and Oxidative Stress

Certain medications may affect immune pathways, liver metabolism, inflammatory signaling, or oxidative stress. In sensitive individuals, this may contribute to scalp inflammation, follicle disruption, or worsening hair shedding.

Chemotherapy and Cytotoxic Drugs

Chemotherapy drugs are among the best-known causes of medication-related hair loss. These drugs target rapidly dividing cancer cells, but they can also affect other rapidly dividing cells, including those in the hair matrix.

This usually causes anagen effluvium. Hair shedding may begin 1 to 3 weeks after treatment starts, with more noticeable loss often occurring around the second month.

Why Chemotherapy Affects Hair Follicles

Hair follicles in the growth phase are highly active. Chemotherapy can interfere with DNA replication or mitotic activity inside these cells. As a result, the follicle may abruptly stop producing a strong hair shaft.

The amount of hair loss varies by drug, dose, treatment schedule, and individual sensitivity.

Common Chemotherapy Drug Classes Linked to Hair Loss

• Alkylating agents: cyclophosphamide, ifosfamide, busulfan.
• Antimetabolites: methotrexate, 5-fluorouracil, cytarabine.
• Topoisomerase inhibitors: doxorubicin, etoposide, irinotecan.
• Mitotic inhibitors: paclitaxel, docetaxel, vincristine.

Chemotherapy-related hair loss may affect the scalp, eyebrows, eyelashes, beard, and body hair.

Is Chemotherapy Hair Loss Permanent?

In most cases, chemotherapy-related hair loss is temporary. Regrowth often begins 1 to 3 months after treatment ends. However, some high-dose or specific regimens may lead to prolonged thinning or, less commonly, permanent follicle changes.

Hormonal Therapy and Endocrine Modulators

Hormones strongly influence the hair growth cycle. Medications that change testosterone, DHT, estrogen, progesterone, or thyroid hormone levels can sometimes affect hair density.

Testosterone Replacement Therapy

Testosterone replacement therapy can accelerate androgenetic alopecia in people who are genetically sensitive to DHT. Hairline recession and crown thinning may become more noticeable after starting treatment.

Finasteride and Dutasteride

Finasteride and dutasteride are used to reduce DHT activity and treat male pattern hair loss. However, some people experience temporary shedding early in treatment as the follicle cycle adjusts.

This early shedding does not always mean the treatment is failing, but it should be monitored carefully.

GnRH Agonists and Antagonists

GnRH medications are used in conditions such as prostate cancer, endometriosis, and other hormone-sensitive disorders. Because they can significantly alter sex hormone levels, thinning or shedding may occur in some patients.

Contraceptives and Fertility Medications

Hair follicles can be sensitive to estrogen and progesterone changes. Starting, stopping, or switching hormonal contraceptives may trigger shedding in susceptible individuals.

• Levonorgestrel IUDs: may be associated with diffuse shedding in sensitive individuals.
• Clomiphene and letrozole: fertility medications that alter hormonal feedback may contribute to temporary shedding in some cases.

Endocrine Therapies in Cancer

Tamoxifen and aromatase inhibitors such as anastrozole and letrozole are used in hormone-receptor-positive breast cancer. By reducing estrogen activity, these treatments may contribute to thinning, especially around the frontal and temporal areas.

Anticoagulants and Blood Thinners

Blood thinners can sometimes contribute to telogen effluvium. Shedding may begin several weeks after treatment starts.

Warfarin and Heparin

Warfarin and heparin have both been linked to medication-related shedding. Warfarin affects vitamin K pathways, while heparin affects clotting through antithrombin activity.

Hair loss associated with these medications is often diffuse and may improve after medication adjustment, but any change must be handled only by the prescribing clinician.

Direct Oral Anticoagulants

Apixaban, rivaroxaban, dabigatran, and edoxaban have also been reported in association with hair loss, although the data is more limited. The mechanism is not fully clear and may involve changes in follicular signaling or microvascular factors.

Proton Pump Inhibitors

Proton pump inhibitors, also called PPIs, include omeprazole, lansoprazole, and pantoprazole. They reduce stomach acid production and are commonly used for acid reflux and ulcers.

Long-term acid suppression may reduce absorption of nutrients important for hair health, including:

• Iron: needed for follicle energy and matrix cell activity.
• Zinc: supports keratin synthesis, immune balance, and scalp health.
• Vitamin B12: important for DNA replication and red blood cell function.

People using PPIs long term who develop fatigue, brittle nails, low energy, digestive symptoms, or unexplained hair thinning may benefit from discussing nutrient testing with a healthcare provider.

Psychiatric Medications

Some psychiatric medications have been associated with diffuse shedding. This can be especially distressing because hair loss may worsen anxiety, mood symptoms, or treatment hesitation.

SSRIs

Selective serotonin reuptake inhibitors such as fluoxetine and sertraline have been linked to telogen effluvium in some case reports.

Hair loss may appear within the first 1 to 3 months of starting treatment or after a dose increase. In some cases, shedding improves after dose adjustment or switching medication, but this should only be done with the prescribing doctor.

Mood Stabilizers

Lithium is a well-documented medication associated with hair shedding in some patients. Possible mechanisms include thyroid disruption and direct effects on follicle cells.

Valproic acid and carbamazepine may also contribute to shedding. Possible contributors include folate depletion, biotin interference, zinc changes, selenium changes, or mitochondrial effects.

Blood Pressure Medications

Blood pressure medications are widely used and often necessary for cardiovascular health. Hair shedding can happen in some users, but it may not be immediately linked to the medication because the timing is often delayed.

Beta Blockers

Beta blockers such as propranolol, metoprolol, and atenolol have been reported in association with telogen effluvium. Shedding may appear 6 to 12 weeks after starting treatment.

The shedding is often mild, but it should still be documented and discussed with the prescribing doctor if it persists.

ACE Inhibitors and ARBs

ACE inhibitors such as lisinopril, enalapril, and ramipril, along with ARBs such as losartan, have occasionally been associated with hair shedding. The mechanism is not fully established but may involve changes in blood flow, inflammatory signaling, or follicle cycling.

Neurological Medications

Anticonvulsants and neurological medications are used for epilepsy, migraine prevention, neuropathic pain, and mood stabilization. Some can affect hair through nutrient metabolism, keratin structure, or follicle cycling.

Phenytoin

Phenytoin has been linked to both excess body hair growth and scalp hair shedding. Possible mechanisms include folate depletion and changes in keratinocyte function.

Carbamazepine and Oxcarbazepine

Carbamazepine and oxcarbazepine may contribute to diffuse telogen effluvium within the first 3 to 6 months of use. Possible contributors include biotin metabolism changes and increased clearance of vitamin D, B vitamins, and trace minerals.

Topiramate and Valproic Acid

Topiramate has been associated with dose-dependent hair loss in some patients. Potential mechanisms may include metabolic changes and altered keratin support.

Valproic acid has also been linked to diffuse or frontal thinning, especially with long-term therapy. It may affect zinc and selenium metabolism, both of which matter for follicle function and antioxidant defense.

Immunosuppressants and Biologics

Immune-modulating medications can affect hair in different ways. Some may cause shedding, while others may support regrowth in autoimmune hair loss conditions such as alopecia areata.

Cyclosporine and Methotrexate

Cyclosporine can cause hirsutism in some people, but it has also been reported in association with shedding depending on dose and context.

Methotrexate can affect folate pathways and DNA synthesis, which may contribute to hair thinning or shedding. This is often dose-dependent and may improve with medical management.

Biologics

Biologics such as adalimumab and infliximab, used for conditions including psoriasis, Crohn’s disease, and other inflammatory disorders, have occasionally been linked to diffuse shedding or alopecia-like reactions.

At the same time, some immune-targeting drugs, such as JAK inhibitors, have shown regrowth effects in alopecia areata. This shows why immune-related hair loss must be evaluated carefully rather than treated with assumptions.

Thyroid Medications

Thyroid hormones are closely tied to hair cycling. Both untreated thyroid disease and shifts in thyroid medication can affect hair growth.

Levothyroxine

Levothyroxine is prescribed to correct hypothyroidism. However, shedding may occur if dosing is too high, too low, or adjusted abruptly. Changes in metabolic rate can temporarily push hair follicles into the shedding phase.

If shedding begins after starting or changing thyroid medication, discuss thyroid labs and symptoms with the prescribing clinician.

Other Medication Categories Linked to Hair Shedding

Statins

Statins such as atorvastatin and simvastatin have rarely been associated with diffuse thinning. The mechanism is not fully clear, but cholesterol pathways are relevant to cell membranes, sebaceous function, and follicle biology.

Antibiotics

Long courses of antibiotics may disrupt gut microbiome balance and contribute to functional B-vitamin or biotin issues in susceptible individuals. Hair loss may appear weeks after extended use, especially when combined with illness, inflammation, or poor intake.

NSAIDs

Non-steroidal anti-inflammatory drugs such as ibuprofen and naproxen have been implicated in rare cases of telogen effluvium, especially with long-term use. Possible mechanisms include prostaglandin pathway changes and microvascular effects.

How to Know if Medication Is Contributing to Hair Loss

The most useful tool is a timeline. Medication-related shedding often follows a pattern.

• Days to weeks: more typical of anagen effluvium, especially with chemotherapy or cytotoxic drugs.
• 6 to 12 weeks: common timing for telogen effluvium after starting or changing medication.
• Several months: possible when nutrient depletion, hormonal changes, or long-term medication effects are involved.

Important clues include a new medication, dose increase, recent illness, surgery, stress, weight loss, menstrual changes, thyroid changes, or digestive symptoms.

What to Do if You Suspect Medication-Related Hair Loss

Do not stop medication suddenly. Many of the drugs listed in this article are medically necessary, and stopping them without guidance can be dangerous.

Instead:

• Write down when the medication started or changed.
• Track when shedding began.
• Photograph the scalp in consistent lighting.
• List all supplements, prescriptions, and over-the-counter drugs.
• Ask your prescriber whether the medication is known to cause shedding.
• Consider bloodwork for ferritin, iron, thyroid markers, vitamin D, B12, zinc, and other relevant markers.
• Consult a trichologist or dermatologist if shedding persists or scalp symptoms are present.

FAQs About Medication-Related Hair Loss

Can medication really cause hair loss?

Yes. Some medications can trigger shedding by shifting hairs into the resting phase, disrupting active growth, altering hormones, affecting nutrient absorption, or increasing inflammation.

How soon does medication-related hair loss start?

It depends on the mechanism. Anagen effluvium can start within days or weeks. Telogen effluvium often appears 6 to 12 weeks after starting or changing a medication.

Is medication-induced hair loss permanent?

Most medication-related shedding is temporary once the trigger is corrected or the body adjusts. However, some treatments, especially certain chemotherapy regimens or long-term inflammatory triggers, may cause prolonged or more persistent changes.

Should I stop my medication if I notice hair loss?

No. Do not stop or change any medication without speaking to the prescribing doctor. Some medications are essential, and stopping suddenly can be dangerous.

What tests should I ask for if I suspect medication-related hair loss?

Useful tests may include ferritin, serum iron, TIBC, vitamin D, B12, zinc, thyroid markers, CBC, and other tests based on your health history and medication profile.

Can a trichologist help with medication-related hair loss?

Yes. A trichologist can review the timing, hair loss pattern, scalp symptoms, nutrition markers, and possible contributing factors. They can also help coordinate next steps with your doctor when needed.

Conclusion

Medication-related hair loss is real, but it is often missed because shedding may appear weeks or months after the drug is started. The most common pattern is diffuse shedding, but the exact presentation depends on the medication, dosage, timing, and the person’s underlying health.

The safest approach is not to stop medication abruptly. Instead, document the timeline, speak with your prescribing clinician, and consider a trichology or dermatology assessment. In many cases, the goal is to protect the necessary medical treatment while identifying and correcting the factors that are affecting hair and scalp health.

References

1. Saleh D, Nassereddin A, Saleh HM, Cook C. Anagen Effluvium. In: StatPearls. StatPearls Publishing; 2025.
2. Hughes EC, Syed HA, Saleh D. Telogen Effluvium. In: StatPearls. StatPearls Publishing; 2025.
3. Owecka B, Tomaszewska A, Dobrzeniecki K, Owecki M. The Hormonal Background of Hair Loss in Non-Scarring Alopecias. Biomedicines. 2024;12(3):513.
4. Almohanna HM, Ahmed AA, Tsatalis JP, Tosti A. The Role of Vitamins and Minerals in Hair Loss: A Review. Dermatology and Therapy. 2019;9(1):51-70.
5. Du F, Li J, Zhang S, Zeng X, Nie J, Li Z. Oxidative stress in hair follicle development and hair growth. Journal of Cellular and Molecular Medicine. 2024;28(12):e18486.
6. Overview: Hair loss in chemotherapy. InformedHealth.org. Institute for Quality and Efficiency in Health Care; 2023.
7. Alkylating Agents. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
8. Lansiaux A. Antimetabolites. Bulletin du Cancer. 2011;98(11):1263-1274.
9. Pommier Y. DNA Topoisomerase I Inhibitors. Chemical Reviews. 2009;109(7):2894-2902.
10. Hair Loss Due to Cancer Treatment. Pharmacy Times. 2015.
11. Rebora A, Guarrera M. Why Do Not All Chemotherapy Patients Lose Their Hair? Skin Appendage Disorders. 2021;7(4):280-285.
12. Tawanwongsri W, Desai DD, Nohria A, Shapiro J, Lo Sicco KI. Hair loss in athletic testosterone use in males. International Journal of Dermatology. 2025;64(4):654-658.
13. Asfour L, Cranwell W, Sinclair R. Male Androgenetic Alopecia. In: Endotext. MDText.com, Inc.
14. Kauschansky A, Lurie R, Ingber A. Hair loss in children on long-acting gonadotropin-releasing hormone agonist treatment. Acta Dermato-Venereologica. 1997;77(4):333.
15. Paterson H, Clifton J, Miller D, Ashton J, Harrison-Woolrych M. Hair loss with use of the levonorgestrel intrauterine device. Contraception. 2007;76(4):306-309.
16. Kamili NAH, Howard J, Radi R, Krueger LD. Alopecia as a side effect of fertility treatments in women. International Journal of Women’s Dermatology. 2025;11(2):e208.
17. Karatas F, Sahin S, Sever AR, Altundag K. Management of hair loss associated with endocrine therapy in patients with breast cancer. SpringerPlus. 2016;5:585.
18. Watras MM, Patel JP, Arya R. Traditional Anticoagulants and Hair Loss. Drugs Real World Outcomes. 2016;3(1):1-6.
19. Weyand AC, Shavit JA. Agent specific effects of anticoagulant induced alopecia. Research and Practice in Thrombosis and Haemostasis. 2017;1(1):90-92.
20. Heidelbaugh JJ. Proton pump inhibitors and risk of vitamin and mineral deficiency. Therapeutic Advances in Drug Safety. 2013;4(3):125-133.
21. Park SY, Na SY, Kim JH, Cho S, Lee JH. Iron Plays a Certain Role in Patterned Hair Loss. Journal of Korean Medical Science. 2013;28(6):934-938.
22. Kil MS, Kim CW, Kim SS. Analysis of Serum Zinc and Copper Concentrations in Hair Loss. Annals of Dermatology. 2013;25(4):405-409.
23. Krugluger W, Stiefsohn K, Laciak K, Moser K, Moser C. Vitamin B12 Activates the Wnt-Pathway in Human Hair Follicle Cells. Journal of Cosmetics, Dermatological Sciences and Applications. 2011;1(2):25-29.
24. Li CY, Dai YX, Chang YT, et al. Proton pump inhibitors are associated with increased risk of alopecia areata. Journal of the American Academy of Dermatology. 2020;83(5):1460-1462.
25. Kıvrak Y, Yağcı İ, Üstündağ MF, Özcan H. Diffuse Hair Loss Induced by Sertraline Use. Case Reports in Psychiatry. 2015;2015:703453.
26. Yesudian P. Lithium in Trichology: A Double Edged Weapon. International Journal of Trichology. 2015;7(1):1.
27. Tomita T, Goto H, Yoshida T, Tanaka K, Sumiya K, Kohda Y. Dose-dependent valproate-induced alopecia. Indian Journal of Pharmacology. 2015;47(6):690-692.
28. Pitton Rissardo J, Fornari Caprara AL, Casares M, Skinner HJ, Hamid U. Antiseizure Medication-Induced Alopecia. Medicines. 2023;10(6):35.
29. Tatu AL, Elisei AM, Chioncel V, Miulescu M, Nwabudike LC. Immunologic adverse reactions of beta-blockers and the skin. Experimental and Therapeutic Medicine. 2019;18(2):955-959.
30. Kataria V, Wang H, Wald JW, Phan YL. Lisinopril-Induced Alopecia. Journal of Pharmacy Practice. 2017;30(5):562-566.
31. Yerawar C, Deokar PG, Noone B. Reversible Hair Loss due to Levothyroxine Overdose. Indian Journal of Endocrinology and Metabolism. 2019;23(6):652-653.
32. Segal AS. Alopecia associated with atorvastatin. The American Journal of Medicine. 2002;113(2):171.
33. Jung JW, Park SY, Kim H. Drug-Induced Vitamin Deficiency. Annals of Clinical Nutrition and Metabolism. 2022;14(1):20-31.
34. Shin DW. The physiological and pharmacological roles of prostaglandins in hair growth. Korean Journal of Physiology and Pharmacology. 2022;26(6):405-413.

About the Author

Dr. Samuel Sarmiento Author

Dr. Samuel Sarmiento is a physician with a rich background in clinical medicine, public health, and research. He completed his surgical internship at the Mayo Clinic, where he gained invaluable experience in one of the world's most renowned healthcare institutions. Recognizing the need to broaden his expertise beyond clinical practice, he pursued dual master’s degrees in Public Health and Business Administration at Johns Hopkins University, followed by a postdoctoral fellowship in clinical outcomes research within the Department of Plastic Surgery. View Full Profile